Enzymes are central to both research and routine clinical testing
Reactomix is a start-up based in Granada, Spain. We are focussed on transforming our understanding of enzymes in research as well as in the clinic, with the goal of developing new diagnostics and therapeutics and improving the outcomes of people with enzymopathies.
Enzymes are very specific and highly efficient biological catalysts. Biological reactions without enzymes would be so slow that the human body would not be able to function. Alterations in enzyme activity, most notably deficiencies are a cause of many pathological states called enzymopathies. These states include Lysosomal Storage Disorders and Innate Errors of Metabolism, cancers, CNS disorders and diseases of the gut.
Most enzymes are part of the proteome, but despite their central role in metabolism, there has been no analytical platform that can directly measure enzymatic activity across a very wide range of enzyme reactions, UNTIL NOW.
Our highly multiplexed enzyme activity panels represent a disruptive breakthrough in omics research. The array-based human enzyme panel (EnzyPathTM) can analyze activity levels of 1800 enzymes in a single test. A human gut microbiome panel is also in development (EnzyBiomeTM).
Our base technology is validated and robust and makes large scale, standardizable testing of enzyme activity practical. Moreover, the smaller sample volumes required, compared to current techniques (up to 50x less) make the application of the technology even greater.
The tests are extremely sensitive compared to existing techniques and work with a wide range of sample matrices. We are focused on research centered on direct analysis of enzymatic activity at large scale and our technology is uniquely suited to the purpose.
Our goal is to help reduce the diagnostic odyssey from Years to Days for as many people as possible
There are more than 700 defined disorders that make up the category of IEMs, with more being added each year. Whilst they are individually rare, taken together they have a combined incidence of 1 in 1,500 births. They are also a significant cause of non-communicable deaths in children, accounting for 0.4% of all child deaths globally.
IEMs are caused by the reduction or absence of enzyme activity in diverse metabolic pathways. These disorders are also referred to as enzymopathies.
These enzyme deficiencies present clinically in a wide variety of ways. Many disorders are treatable if diagnosed early, but limited screening, heterogeneity in clinical presentation and overlap with many other diseases means that clinical diagnosis of IEMs is difficult. Objective biochemical diagnosis is critical.
Our interest in IEMs began with Lysosomal Storage Disorders and our desire to develop a broad multiplex array that can facilitate testing for alterations in all enzyme activities related to Lysosomal Storage Disorders.
We are currently researching patterns of enzyme activity related to cancer metabolism and its phenoconversion, staging and progression and metastases. We are focusing initially on Breast Cancer and Lung Cancer, but we intend to cover many other disease states.
At Reactomix our objective is to increase our understanding of the role of enzyme activity and its alterations and the role that this plays in both health and illness.
We are looking for global collaborations with other companies, research institutions and healthcare centers to make new discoveries, help drive the development of new diagnostics and therapeutics and ultimately improve outcomes based on knowledge of enzyme activities.
If you are interested in business development and partnering activities with us, or are interested in investing in us, please reach out to us below.
Camino de Ronda 133